Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine
Clinical trial NCT06263387 · UNKNOWN
Trial details
- NCT number
- NCT06263387
- Sponsor
- French Innovative Leukemia Organisation
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2024-07-04
- Primary completion
- 2024-12-31
- Enrollment
- 230
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.